Search Results for: "Clinic Roundup"
-
Clinic Roundup
The data from the first three subjects in a six-patient cohort showed a favorable safety profile and a reduction in the average daily dose of L-DOPA "equivalent" therapyBioWorld Today | Friday, August 5, 2011 -
Clinic Roundup
The data showed that ganetespib had clinical activity as a single agent and a good safety profileBioWorld Today | Friday, July 8, 2011 -
Clinic Roundup
The study also indicated a favorable safety profile and successful intercourse, as measured by SEP 3, was observed as early as 15 minutes after dosing, without restrictions on food or alcohol, the company saidBioWorld Today | Monday, June 20, 2011 -
Clinic Roundup
QRxPharma Ltd., of Sydney, Australia, completed Study 022, an exploratory Phase III study comparing the tolerability and safety profile of MoxDuo IR to equi-analgesic doses of either morphine or oxycodone alone, with data showing that MoxDuo effectively reduced pain with less respiratory depression...The study is designed primarily to evaluate the HbA1c-lowering effects, while the cardiovascular safety profile will be monitored according to FDA guidanceBioWorld Today | Wednesday, June 15, 2011 -
Clinic Roundup
Amgen Inc., of Thousand Oaks, Calif., reported interim results from a single-arm study evaluating Nplate (romiplostim) in adults with primary immune thrombocytopenia, demonstrating that the drug induced a rapid platelet response with a good safety profile in subjects with low platelet counts and bleeding symptomsBioWorld Today | Monday, June 13, 2011 -
Clinic Roundup
ProSavin also continued to show a favorable safety profileBioWorld Today | Tuesday, May 24, 2011 -
Clinic Roundup
The company said the double-blind study will evaluate the pharmacokinetic and safety profile of escalating doses of RG3039 in as many as 40 healthy volunteersBioWorld Today | Friday, May 20, 2011 -
Clinic Roundup
The company said that the open-label, dose-escalating study is sponsored in part by the Leukemia & Lymphoma Society's Therapy Acceleration Program and will be conducted in patients with relapsed or refractory AML or MDS to evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503BioWorld Today | Friday, May 13, 2011 -
Clinic Roundup
Can-Fite BioPharma Ltd., of Petah-Tikva, Israel, said Phase I/II interim analysis data for drug candidate CF102 in hepatocellular carcinoma showed a favorable safety profile in a patient population with primary liver cancer and Child-Pugh cirrhosis classes A and BBioWorld Today | Thursday, May 12, 2011 -
Clinic Roundup
Stem Cell Therapeutics Corp., of Calgary, Alberta, enrolled the first patient in an open-label Phase IIa traumatic brain injury (TBI) trial testing the safety profile of NTx-428, a human chorionic gonadotropin and epoeitin alfa therapy, when administered to patients who have sustained a TBIBioWorld Today | Monday, May 2, 2011 -
Clinic Roundup
V-101 also demonstrated a safety profile similar to placeboBioWorld Today | Wednesday, April 20, 2011 -
Clinic Roundup
CRMD001 appears to have a favorable safety profile, according to a blinded review of the dataBioWorld Today | Monday, April 4, 2011 -
Clinic Roundup
Vertex Pharmaceuticals Inc., of Cambridge, Mass., reported results from a Phase II study of VX-765, a caspase-1 inhibitor, in 60 patients with treatment-resistant epilepsy, with data showing a similar safety profile for VX-765 as compared to placebo, the primary endpointBioWorld Today | Friday, March 11, 2011 -
Clinic Roundup
The drug's safety profile was consistent with that seen in previous studiesBioWorld Today | Monday, March 7, 2011 -
Clinic Roundup
In that study, safety was the primary endpoint, and the drug was generally well tolerated, with a safety profile consistent to both PRE-SURGE studies. (See BioWorld Today, June 10, 2010BioWorld Today | Tuesday, March 1, 2011 -
Clinic Roundup
Overall, there was a comparable safety profile between the three groups in the study, and Posidur appeared well toleratedBioWorld Today | Thursday, February 10, 2011 -
Clinic Roundup
The study also confirmed that the treatment had a favorable safety profileBioWorld Today | Wednesday, February 2, 2011 -
Clinic Roundup
A preliminary safety analysis showed that the safety profile was consistent with previous studiesBioWorld Today | Monday, January 31, 2011 -
Clinic Roundup
The study will seek to determine the maximum tolerated dose and recommended Phase II dose of LOR-253, as well as the compound's safety profile, antitumor activity and pharmacokineticsBioWorld Today | Friday, January 14, 2011 -
Clinic Roundup
All doses were well tolerated with a favorable safety profileBioWorld Today | Wednesday, January 12, 2011
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.